NASDAQ · Biotechnology

IMNM (IMNM) Stock

$23.22 +2.83% NASDAQ: IMNM Healthcare

Valuation

MetricValue
Price$23.22
Market Cap$2.22B
P/E Ratio-8.13
P/B Ratio2.98
P/S Ratio468.10
EPS (TTM)$-2.43
52-Week High$27.65
52-Week Low$7.96
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-33.44%
ROA-31.04%
ROCE-33.75%
Gross Margin-3057.14%
Operating Margin-3057.14%
Net Margin-55.94%
Debt/Equity0.01
Current Ratio14.69

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$14.0M$9.0M$7.0M
Operating Profit$-25.0M$-37.0M$-110.0M$-306.0M$-214.0M
Net Profit$-25.0M$-37.0M$-107.0M$-293.0M$-212.0M
EPS$-2.14$-3.09$-5.38$-5.00$-2.43
Op Margin——-781.4%-3382.4%-3084.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$58.0M$24.0M$149.0M$240.0M$683.0M
Total Liabilities$10.0M$7.0M$29.0M$59.0M$49.0M
Cash$49.0M$20.0M$99.0M$143.0M$653.0M
Borrowings$0$0$2.0M$5.0M$4.0M

Latest News

What This Immunome Sale Means a Day Before a Big FDA Milestone Motley Fool · Jul 12, 2026 Immunome Stock Up 32% in a Month: Here's What You Should Know Zacks · Jul 10, 2026 Immunome Says FDA Accepted NDA for Desmoid Tumors Drug MT Newswires · Jul 8, 2026 Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors Business Wire · Jul 8, 2026 Immunome Insider Sold Shares Worth $2,412,522, According to a Recent SEC Filing MT Newswires · Jul 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-18.0M$-29.0M$-8.0M$-111.0M$-191.0M
Investing Cash Flow$0$0$-31.0M$-139.0M$51.0M
Financing Cash Flow$1.0M$0$116.0M$-9.0M$0
Net Cash Flow$9.0M$-29.0M$78.0M$45.0M$510.0M
Free Cash Flow$-18.0M$-29.0M$-8.0M$-164.0M$-201.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-10.94%
Quick Ratio21.68
Interest Coverage—
Return 1Y106.68%
Return 3Y221.35%
Return 5Y34.43%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABCL $6.93 +6.13% -5.91 $2.12B 0.00%
BHVN $14.07 +3.19% -6.11 $2.12B 0.00%
CLDX $35.80 +0.63% -7.84 $2.38B 0.00%
MAZE $27.88 -2.82% -8.11 $1.54B 0.00%
NTLA $10.89 +2.06% -3.55 $1.22B 0.00%

About IMNM

IMNM stock trades at $23.22 with a market capitalization of $2.22B. The stock is valued at a price-to-earnings (P/E) ratio of -8.13, price-to-book of 2.98, price-to-sales of 468.10. Over the past 52 weeks the stock has ranged between $7.96 and $27.65, and currently trades 16.0% below its 52-week high.

On profitability, IMNM generates a return on equity (ROE) of -33.44%, return on capital employed of -33.75%, an operating margin of -3057.14%, a net profit margin of -55.94%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides